

Review Article



OPEN ACCESS

Received: Oct 2, 2017

Revised: Dec 19, 2017

Accepted: Dec 21, 2017

*Correspondence to

Bo Zhong

Medical Research Institute, School of
Medicine, Wuhan University, 115 Donghu Road,
Wuhan 430071, China.

E-mail: zhongbo@whu.edu.cn

Copyright © 2018. The Korean Association of
Immunologists

This is an Open Access article distributed
under the terms of the Creative Commons
Attribution Non-Commercial License ([https://
creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/))
which permits unrestricted non-commercial
use, distribution, and reproduction in any
medium, provided the original work is properly
cited.

Conflict of Interest

The authors declare no potential conflicts of
interest.

Abbreviations

AIM, absent in melanoma; ASC, apoptosis-
associated speck-like protein containing a
caspase recruitment domain; cGAS, cyclic
guanosine monophosphate-adenosine
monophosphate synthase; CRL, cullin-RING
E3 ligase; CYLD, cylindromatosis; dsDNA,
double-stranded DNA; DUB, deubiquitinating
enzyme; E1, activating enzyme; E2, conjugating
enzyme; E3, ligase; IFI, interferon-induced
protein; IFN, interferon; IKK, I κ B kinase; IRF,
interferon regulatory factor; ISG, interferon-
stimulated gene; MAVS, mitochondrial
antiviral-signaling protein; MDA, melanoma
differentiation-associated gene; MTA,

Regulation of Cellular Antiviral Signaling by Modifications of Ubiquitin and Ubiquitin-like Molecules

Kang Li¹, Bo Zhong^{1,2,*}

¹Department of Immunology, Medical Research Institute, School of Medicine, Wuhan University, Wuhan
430071, China

²Department of Virology, College of Life Sciences, Wuhan University, Wuhan 430072, China

ABSTRACT

The initiation of cellular antiviral signaling depends on host pattern-recognition receptors (PRRs)-mediated recognition of viral nucleic acids that are known as classical pathogen-associated molecular patterns (PAMPs). PRRs recruit adaptor proteins and kinases to activate transcription factors and epigenetic modifiers to regulate transcription of hundreds of genes, the products of which collaborate to elicit antiviral responses. In addition, PRRs-triggered signaling induces activation of various inflammasomes which leads to the release of IL-1 β and inflammation. Recent studies have demonstrated that PRRs-triggered signaling is critically regulated by ubiquitin and ubiquitin-like molecules. In this review, we first summarize an updated understanding of cellular antiviral signaling and virus-induced activation of inflammasome and then focus on the regulation of key components by ubiquitin and ubiquitin-like molecules.

Keywords: Innate immune responses; Signal transduction; Regulation; Ubiquitin; SUMO; NEDD8; ISG15

INTRODUCTION

About 3 decades ago, the late master Charles Janeway Jr. proposed the concept that recognition of pathogen-associated molecular patterns (PAMPs) by pattern-recognition receptors (PRRs) activated effector functions of primitive immune systems prior to the development of adaptive immune responses and played a key role in host defense in both invertebrates and vertebrates (1). Since then, tremendous efforts have been taken to characterize the PAMPs, PRRs and molecules involved in primitive immunity, from which we know that viral nucleic acids are classical PAMPs recognized by at least 2 types of PRRs, membrane-located toll-like receptors (TLRs) and cytosol-located receptors (2). After binding to viral nucleic acids, these PRRs either recruit adaptor proteins or produce immuno-stimulating factors to trigger signaling to activate transcription of hundreds of downstream genes (3). For example, TLR3, TLR7/8, and TLR9 recruit adaptor proteins toll/interleukin-1 receptor-domain containing adaptor-inducing interferon (IFN)- β (TRIF) or myeloid differentiation protein 88 (MyD88) for signal transduction in immune cells such as dendritic cells and macrophages, and cytosolic retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs) recruit adaptor proteins virus-induced signaling adaptor (VISA) (also

mediator of interferon regulatory factor 3 activation; MyD88, myeloid differentiation protein 88; NEDD8, neural precursor cell expressed, developmentally downregulated 8; NEDP1, NEDD8-specific protease 1; NIK, NF- κ B-inducing kinase; NLR, nucleotide oligomerization domain-like receptor; NLRP3, nucleotide oligomerization domain-like receptor family pyrin domain containing 3; OTUB1, OTU domain-containing ubiquitin aldehyde-binding protein 1; PAMP, pathogen-associated molecular pattern; PRR, pattern-recognition receptor; RIG-I, retinoic acid-inducible gene 1; RLR, retinoic acid-inducible gene 1-like receptor; RNF, ring finger protein; ROS, reactive oxygen species; SENP, small ubiquitin-related modifier-specific protease; TBK, Tank-binding kinase; TLR, toll-like receptor; TRIF, Toll/interleukin-1 receptor-domain containing adaptor-inducing interferon- β ; TRIM, tripartite motif containing; Ubc, ubiquitin-conjugating enzyme; UBL, ubiquitin-like molecules; USP, ubiquitin-specific peptidase; VISA, virus-induced signaling adaptor; WWP, WW domain-containing protein

Author Contributions

Conceptualization: Zhong B; Supervision: Zhong B; Visualization: Li K, Zhong B; Writing - original draft: Li K, Zhong B; Writing - review & editing: Li K, Zhong B.

known as mitochondrial antiviral-signaling protein [MAVS], IFN- β promoter stimulator 1 [IPS-1], and caspase recruitment domain [CARD] adapter inducing IFN- β [Cardif]) and function in almost all types of cells (4-7), whereas the double-stranded DNA (dsDNA) sensors cyclic guanosine monophosphate (GMP)-adenosine monophosphate (AMP) synthase (cGAS) and RNA polymerase III generate cyclic GMP-AMP (cGAMP) and 5'ppp RNA which activate MITA (also known as stimulator of IFN genes [STING]), and RIG-I-VISA pathways, respectively (8-13). The adaptor proteins further recruit kinases including the canonical and noncanonical inhibitor of κ B kinases to activate transcription factors IFN regulatory factor (IRF) 3, IRF7, and NF- κ B, which collaborate to induce transcription of type I IFNs and pro-inflammatory cytokines. In addition to TLRs, RLRs, and dsDNA sensors, cytosolic nucleotide oligomerization domain-like receptors (NLRs) are also involved in recognition of viral nucleic acids. It has been reported that NLR family pyrin domain containing 3 (NLRP3) and absent in melanoma 2 (AIM2) detect RNA and DNA viruses and activate apoptosis-associated speck-like protein containing a CARD (ASC)-dependent signaling (14,15). In contrast to induction of gene transcription, ASC-mediated signaling activates caspase 1 which cleaves pro-IL-1 β and pro-IL-18 into mature IL-1 β and IL-18 to trigger robust inflammatory responses.

Ubiquitination is mediated through sequential catalytic reactions by 3 enzymes referred to as activating enzyme (E1), conjugating enzyme (E2), and ligase (E3), leading to the conjugation of mono- or poly-ubiquitin chains on the ϵ -amino (ϵ -NH₂) group of lysine residues in target proteins. It is well recognized that different linkages of polyubiquitin chains exert distinct functions (16). For example, K63-linked ubiquitination of RIG-I catalyzed by tripartite motif containing (TRIM) 25, Riplet (also known as ring finger protein [RNF] 135 and REUL), TRIM4 and MEX3C is believed to promote the activation of RIG-I, whereas K48-linked ubiquitination of RIG-I by RNF125, c-Cbl, and IFN-induced protein (IFI) 35 destabilizes RIG-I.

In addition to ubiquitin, host genome encodes several ubiquitin-like molecules, including small ubiquitin-related modifier (SUMO), neural precursor cell expressed, developmentally downregulated 8 (NEDD8), and IFN-stimulated gene 15 (ISG15), which are powerful regulators of cellular antiviral signaling (17-20). The ubiquitin-like modifications are also mediated by E1, E2, and E3. Specifically, ubiquitin-conjugating enzyme (Ubc) 9, Ubc12, and UbcH8 are well characterized E2s for SUMOylation, NEDDylation, and ISGylation, respectively. It has been reported that these ubiquitin-like modifiers regulate the function of targeted proteins through at least three mechanisms. First, the ubiquitin-like modification interferes with ubiquitination on the same lysine residues of targeted protein, and thereby modulates its activity or stability. Second, the ubiquitin-like modification provides steric obstacles or docking sites, and thereby affecting the assembly of signaling complexes. Third, the ubiquitin-like modification remodels the structures and physical or chemical properties, thereby affecting the function or localization of targeted proteins. For example, SUMOylation of poly(C)-binding protein 2 (PCBP2) promotes its translocation from nucleus to cytosol, where it associates with and degrades VISA, whereas SUMOylation of IRF3 on Lys70/87 prevents its ubiquitination and degradation (21,22).

Considering the important roles of ubiquitin and ubiquitin-like modifications in cellular antiviral responses, it is conceivable that the reverse deconjugation process of ubiquitin and ubiquitin-like modifiers would be as equally important. The reversal reactions are exerted by deubiquitinating enzymes (DUBs) which remove ubiquitin modifications and ubiquitin-like proteases including sentrin/SUMO-specific protease (SENP), NEDD8-specific protease 1 (NEDP1, also known as SENP8 or DEN1) and COP9 signalosome complex subunit 5 (CSN5), and UBP43 (also known as ubiquitin-specific peptidase [USP] 18) which catalyze removal

of SUMO, NEDD8, and ISG15 from the target proteins, respectively (17-20). Their roles in cellular innate antiviral signaling have been emerging (19,23).

In this review, we will summarize the most recent advancement in our understanding of innate cellular antiviral signaling and then focus on the regulation of key components involved in these pathways by ubiquitin and ubiquitin-like molecules.

VIRUS-TRIGGERED PRRS-MEDIATED SIGNALING

Signaling leading to type I IFN induction

The induction of type I IFNs is one of the hallmarks after viral infection and is dependent on the transcription factors IRF3/7 and NF- κ B, which are activated by the PRR-adaptor-kinase signaling cascades (**Fig. 1**). Binding of the PRRs to viral nucleic acids induces dimerization or oligomerization of adaptor proteins, which further recruit kinases in a ubiquitin- and phosphorylation-dependent manner. It has been reported that VISA is ubiquitinated by TRIM31 and MITA is conjugated with TRIM56- or TRIM32-mediated K63-linked ubiquitination and AMFR/gp98-mediated K27-linked ubiquitination, all of which are essential for the recruitment of Tank-binding kinase (TBK) 1 and I κ B kinase (IKK) ϵ (2-27). In addition, the TRAF family




Figure 1. Virus-triggered PRRs-mediated signaling pathways leading to type I IFN and IL-1 β induction.

proteins, TRAF2, TRAF3, TRAF5, and TRAF6 and death domain-containing (DD) family proteins, tumor necrosis factor receptor-associated death domain protein (TRADD), Fas-associated death domain protein (FADD), and receptor-interacting protein (RIP) act as scaffolding proteins to promote the recruitment of TBK1 and IKK ϵ and their ubiquitination is required for this process (28,29). In the adaptor-scaffold-kinase complex, TBK1 or IKK ϵ phosphorylates conserved serine residues on TRIF, VISA, or MITA, thereby providing a negative charged platform to recruit the transcription factor IRF3 through the charged surfaces on the C terminus of IRF3 (30). Although it is believed that IRF7 is activated in a manner similar to IRF3, the direct experimental evidence is still lacking. In contrast, IRF7 undergoes ubiquitination by TRAF6 and is phosphorylated by IKK α in plasmacytoid dendritic cells (pDCs) downstream of TLR7 or TLR9 and MyD88, which induces robust expression of IFN- α (31-33).

The ubiquitination and oligomerization of adaptor proteins also recruits TAK1 and IKK $\alpha/\beta/\gamma$ complex in a manner decedent on the TRAF and DD family proteins. The IKK $\alpha/\beta/\gamma$ complex phosphorylates I κ B α that results in its ubiquitination and degradation, releasing the p65/p50 dimer from the cytoplasm into nucleus. IKK α/β also phosphorylates p65 to further enhance its transcriptional activity, as inhibition of IKK α/β -p65 association by INK160 impairs p65 activation and induction of type I IFNs (34). On the other hand, infection by RNA viruses activates NF- κ B-inducing kinase (NIK)-IKK α which phosphorylates p100 and induces the partial degradation of p100 into p52 and p52 enters into nucleus and binds to the promoter of *IFNB* gene to inhibit its transcription (35). How viral infection triggers NIK-IKK α activation is less clear but at least requires the viral RNA receptor RIG-I. In addition, whether and how the NIK-IKK α -p100 axis is activated upon DNA virus infection are of great interest and await for further investigations.

Signaling leading to IL-1 β production

Accumulating evidence suggests that the induction of IL-1 β is another hallmark after viral infection, which is essential for host defense against viruses and involves a 2-step transcription and cleavage process (Fig. 1) (36). The transcription of pro-IL-1 β depends on viral infection-induced activation of NF- κ B, whereas the maturation of IL-1 β requires activation of inflammasomes which are multi-component complex consisting of PRRs, adaptor protein ASC and caspase 1 (36,37). The PRRs initiating the inflammasome assembly after viral infection include NACHT, LRR, and PYD domains-containing protein 3 (NLPR3), AIM2, RIG-I, and IFI16. AIM2 and IFI16 are dsDNA sensors that directly recruit ASC and caspase 1, leading to cleavage of pro-IL-1 β into mature IL-1 β (38,39). It is thus conceivable that infection of various DNA viruses and retroviruses (whose reverse transcription generates ssDNA that adopts stem-loop structures) activate the AIM2 or IFI16 inflammasome to induce IL-1 β production (40). However, it is less clear whether and how the AIM2 and IFI16 inflammasomes function cooperatively or in a virus-specific manner. For example, AIM2 inflammasome-induced IL-1 β induction is essential for defense against vaccinia virus and mouse cytomegalovirus, whereas IFI16 inflammasome detects HSV-1 infection to trigger IL-1 β induction (38,40). One possible explanation for this is that diverse inflammasomes increase the chance to counteract the evading strategies evolved by different viruses.

In addition to inducing transcription of the genes encoding ASC, pro-caspase 1 and pro-IL-1 β , RIG-I also engages inflammasome activation by directly interacting with ASC (41). However, whether similar mechanisms apply to RIG-I mediated recruitment of VISA and ASC requires further investigations. TLR7 and TLR8 are required for inflammasome activation in human monocytes and macrophages after HIV or HCV infection, and it is unknown whether they function to induce pro-IL-1 β and/or ASC transcription or directly activate ASC-dependent inflammasomes (42). It is likely that during TLRs or RLRs signaling and viral replication, a number of danger

signals such as reactive oxygen species (ROS) and ion influx or efflux are generated as byproducts which are detected by other sensors such as NLRP3 to activate inflammasomes (discussed below). Whether exist cytoplasmic RNA sensors that simultaneously recognize RNA and associates with ASC-pro-caspase 1 to activate inflammasome is of great interest.

NLRP3 belongs to NLR family and directly interacts with ASC and pro-caspase 1 to form an inflammasome, in which pro-caspase 1 is cleaved into active caspase 1 to cleave pro-IL-1 β into IL-1 β (43). Unlike TLRs, RLRs or cytoplasmic DNA sensors that directly bind to viral nucleic acids, NLRP3 lacks a nucleic acid binding motif and senses a variety of danger signals such as ROS, ion imbalance, cathepsin B and extracellular ATP for activation (43). Viral infection activates the danger signals either by triggering nucleic acid sensors-mediated signaling or by the virus-encoding viroporins. For example, influenza virus infection induces ROS during viral internalization or by activating RIG-I or TLR7 signaling and the ion channel protein M2 encoded by the influenza genome disturbs the ionic milieu in the cytoplasm, whereas influenza virus infection-induced cell death leads to release of ATP to the local infected matrix (44,45). DNA viruses such as adenovirus and myxoma virus trigger the induction of ROS and cathepsin B to activate the NLRP3 inflammasome (46). Thus, the NLRP3 inflammasome provides a house-keeping guard in detection of danger signals generated during infection and replication of DNA and RNA viruses, although the precise mechanism of NLRP3 inflammasome activation in response to the danger signals requires additional investigations.

The signaling pathways involved in the induction IFNs and IL-1 β cross-talk with each other extensively. The kinase IKK ϵ phosphorylating IRF3 also phosphorylates ASC at Ser58 to promote the translocation of ASC into cytoplasm, and the kinase IKK α phosphorylating I κ B α phosphorylates ASC at Ser19/193 to inhibit its oligomerization (47). Recently, it has been demonstrated that inflammasome-activated caspase 1 cleaves cGAS and thereby impair DNA virus-induced expression of type I IFNs (48). It seems that the mutual regulation facilitates appropriate cellular immune responses against invading viruses.

REGULATION OF VIRUS-TRIGGERED PRRS-MEDIATED SIGNALING

Virus-triggered PRRs-mediated signaling must be tightly controlled to mount protective immune responses and avoid harmful immune pathology. Cumulative evidence has suggested that posttranslational modifications by ubiquitin and ubiquitin-like molecules are critically involved in this process by conjugating to the ϵ -NH₂ group of lysine residues through the conserved C terminal-GG motif (Fig. 2) (49). Here we will discuss the most

		E2s	Deconjugating enzymes
Ubiquitin:	69-VLRLRGG-76	Ubc13, etc	DUBs
NEDD8:	70-VLALRGG-76	UBE2M/UBE2F	SENp8/CSN5
ISG15:	151-NLRLRGG-157	UbcH8	USP18
Sumo1:	89-EVYQEQTGG-97	Ubc9	SENp1/2/3/7
Sumo2:	85-DVFQQQTGG-93		
Sumo3:	122-DVFQQQTGG-130		
Sumo4:	85-DVFQQPTGG-93		

Figure 2. The C terminal conserved amino acids of ubiquitin and ubiquitin-like molecules.

recent progresses on the regulation of virus-triggered PRRs-mediated signaling by ubiquitination, ISGylation, SUMOylation, and NEDDylation (**Table 1**).

Table 1. Ubiquitin and ubiquitin-like modifications in virus-triggered PRRs-mediated signaling pathways

Target molecules	E3 ligases-mediated ubiquitination	Modification sites	References
PRRs			
RIG-I	RNF122 (K48 linkage)	Lys115, Lys 146	Wang et al. (56)
	CHIP (K48 linkage)	ND	Zhao et al. (136)
	CypA-TRIM25 (K63 linkage)	Lys172	Liu et al. (50)
			Gack et al. (51)
	p97-RNF125 (K48 linkage)	Lys181	Hao et al. (55)
	TRIM40 (K27 and K48 linkage)	ND	Zhao et al. (59)
	Ube2D3, Ube2N (K63 linkage)	Lys48, Lys96, Lys172	Shi et al. (52)
	MUL1 (SUMOylation)	ND	Doiron et al. (105)
	USP15 (K63 linkage)	-	Zhang et al. (60)
	UbcH8 (ISGylation)	ND	Arimoto et al. (118)
MDA5	TRIM38 (SUMOylation)	Lys96, Lys888	Hu et al. (106)
	SENP2	-	-
	TRIM65 (K63 linkage)	Lys743	Lang et al. (67)
	TRIM40 (K27 and K48 linkage)	Lys23, Lys43, Lys68	Zhao et al. (59)
	PIAS2 β (SUMOylation)	ND	Fu et al. (104)
	TRIM38 (SUMOylation)	Lys43, Lys865	Hu et al. (106)
	RNF185 (K27 linkage)	ND	Wang et al. (68)
	TRIM38 (SUMOylation)	Lys83, Lys231, Lys479	Hu et al. (107)
	SENP2	-	-
	SENP7	Lys335, Lys372, Lys382	Cui et al. (108)
cGAS	USP14 (K48 linkage)	Lys414	Chen et al. (69)
	FBXL12 (K48 linkage)	Lys689	Han et al. (71)
	MARCH7 (K48 linkage)	ND	Yan et al. (72)
AIM2, IFI16	ND	-	-
Adaptor proteins			
TRIF	TRIM38 (K48 linkage)	Lys228	Xue et al. (73)
			Hu et al. (74)
	WWP2 (K48 linkage)	ND	Yang et al. (75)
MyD88	TRIM32 (ubiquitin-independent)	-	Yang et al. (76)
	CYLD (K63 linkage)	Lys231	Lee et al. (77)
	Smurf1/2 (K48 linkage)	Lys231, Lys262	Naiki et al. (78)
			Strickson et al. (79)
VISA	Pellino (K48 linkage)	ND	Ji et al. (80)
	ND (NEDDylation)	ND	Yan et al. (131)
	Tetherin-MARCH8 (K48 linkage)	Lys7	Jin et al. (82)
	TRIM31 (K63 linkage)	Lys10, Lys311, Lys461	Liu et al. (24)
MITA	IRTKS-PCBP2 (SUMOylation)	-	Xia et al. (21)
	TRIM29 (K48 linkage)	ND	Xing et al. (83)
	MUL1 (K63 linkage)	Lys224	Ni et al. (84)
	TRIM30 α (K48 linkage)	Lys275	Wang et al. (85)
	AMFR (K27 linkage)	-	Wang et al. (25)
	USP21 (K27/63 linkage)	-	Chen et al. (88)
	USP18-USP20 (K48 linkage)	-	Zhang et al. (86)
	USP13 (K27 linkage)	-	Sun et al. (87)
	TRIM38 (SUMOylation)	Lys338	Hu et al. (107)
	TRAF3 (K63 linkage)	Lys174	Guan et al. (95)
ASC	ER α (K48 linkage)	ND	Wang et al. (90)
TRAF3, TRAF6	cIAP1/2 (K63 and K48 linkage)	-	Mao et al. (89)
	USP25 (K48 linkage)	-	Lin et al. (93)
	MYSM1 (K63 linkage)	-	Panda et al. (94)
	HSCARG-OTUB1 (K48 linkage)	-	Peng et al. (91)

(continued to the next page)

Table 1. (Continued) Ubiquitin and ubiquitin-like modifications in virus-triggered PRRs-mediated signaling pathways

Target molecules	E3 ligases-mediated ubiquitination	Modification sites	References
Kinases and transcription factors			
TBK1	MIB2 (K63 linkage)	ND	Ye et al. (137)
	RNF128 (K63 linkage)	Lys30, Lys401	Song et al. (98)
	USP1-UAF1 (K48 linkage)	ND	Yu et al. (138)
	DYRK2-DTX4 (K48 linkage)	Lys670	Cui et al. (139)
IRF3	ND (SUMOylation)	Lys694	An et al. (96)
	c-Cbl (K48 linkage)	ND	Saul et al. (140)
	LUBAC (linear)	ND	Zhao et al. (99)
	ND (SUMOylation)	Lys193, Lys313	Chattopadhyay et al. (100)
	PIAS1 (SUMOylation)	Lys152	Kubota et al. (110)
	SENPA2	ND	Li et al. (112)
	HERC5 (ISGylation)	Lys70, Lys87	Yang et al. (22)
IRF7	TRIM28 (SUMOylation)	Lys193, Lys360, Lys366	Lu et al. (119)
	ND (SUMOylation)	Lys193, Lys360, Lys366	Shi et al. (120)
	TRAF6 (K63 linkage)	Lys444, Lys446	Liang et al. (111)
	A20 (K63 linkage, unanchored)	Lys406	Kubota et al. (110)
Pro-IL-1 β	TRAF6 (K63 linkage)	Lys44, Lys446, Lys452	Ning et al. (101)
	A20 (K63 linkage, unanchored)	Lys133	Duong et al. (141)

ND, not determined.

UBIQUITINATION AND DEUBIQUITINATION

Regulation of PRRs

It has been shown that TRIM25 catalyzes K63-linked ubiquitination of RIG-I at Lys172, and this process is promoted by the peptidyl-prolyl cis/trans isomerase cyclophilin A (CypA) (50,51), leading to potentiated recruitment of VISA and induction of type I IFNs. In addition to TRIM25, multiple E3s such as TRIM4, Riplet, and MEX3C have been suggested to mediate K63-linked ubiquitination and activation of RIG-I. Specifically, Ube2D3 promotes Riplet-mediated conjugation of polyubiquitin chains to RIG-I and Ube2N facilitates Riplet to synthesize unanchored polyubiquitin chains, which are prerequisites for full activation of RIG-I (52). These E3s may function in a synergistic way, as supported by recent studies that use a systemic biology approach to demonstrate that TRIM4 and TRIM25 exhibit dose-dependent synergism for RIG-I activation and catalyze ubiquitination of RIG-I on multiple lysine residues in a hierarchical way, which provides an efficient and optimal synergistic regulatory module in antiviral immune responses (53,54). Recently, it has been reported that the E3 ubiquitin ligase RNF122 delivers K48-linked ubiquitination to the Lys115 and Lys146 residues of RIG-I and p97 recruits RNF125 to ubiquitinate RIG-I at Lys 181 and thereby promote RIG-I degradation, leading to the inhibition of RIG-I-mediated signaling (55,56). RNF125 and c-Cbl have been shown to catalyze K48-linked ubiquitination and degradation of RIG-I (57,58). A more recent study has shown that TRIM40 catalyzes K27- and K48-linked ubiquitination of RIG-I, leading to its proteasome-dependent degradation and suppression of antiviral responses (59). However, it is unknown whether the negative ubiquitin signals on RIG-I also conform to the synergistic regulatory model.

USP15 is a DUB that deubiquitinates K63-linked ubiquitination of RIG-I, thereby turning down type I IFNs induction (60). Interestingly, however, results from another study suggest that USP15 deconjugates K48-linked ubiquitin chains from TRIM25 and promotes its stability and thus facilitates K63-linked ubiquitination of RIG-I and virus-triggered expression of type I IFNs (61). The reasons for discrepancies between these 2 studies are unknown. In addition, a number of DUBs including cylindromatosis (CYLD), USP3, USP21, USP4, and USP17 are also involved in the regulation of K63- or K48-linked ubiquitination of RIG-I (62-66). It is

so far unclear whether these DUBs function redundantly or hierarchically in cellular innate antiviral responses.

The observation that TRIM25 targets RIG-I but not melanoma differentiation-associated gene (MDA) 5 for ubiquitination prompts investigators to characterize E3s that are responsible for MDA5 ubiquitination and activation. The identification of TRIM65 as the E3 catalyzing K63-linked ubiquitination of MDA5 has filled in gap in our understanding of the mechanisms by which MDA5 triggers signaling. Unlike the activation of RIG-I requires ubiquitination on the N terminal CARD domain, TRIM65 promotes K63-linked ubiquitination of MDA5 at the C terminal Lys743, which is critical for MDA5 oligomerization and activation. Trim65 deficiency abolishes MDA5 agonist- or encephalomyocarditis virus (EMCV)-induced type I IFN production (67). Whether there exist E3s specifically regulating the stability of MDA5 and whether there are DUBs counteracting this process require further investigations.

The DNA sensor cGAS undergoes K27-linked ubiquitination by RNF185 after HSV-1 infection, which promotes its enzymatic activity (68). Interestingly, cGAS is modified by K48-linked ubiquitination at Lys414, which leads to p62-dependent selective autophagic degradation. TRIM14 recruits USP14 to deconjugate such a modification, thereby promote cGAS signaling (69). Upon challenge, AIM2 and NLRP3 undergo ubiquitination and recruit the adaptor p62 for autophagic degradation (70), and blocking autophagy potentiates AIM2 and NLRP3 inflammasome activity. While FBXL2 and MARCH7 target NALP3 for ubiquitination and degradation (71,72), the E3s responsible for the degradative ubiquitin modification of cGAS and AIM2 remain to be characterized.

Regulation of adaptor proteins

The TLR3-TRIF and TLR7/8-MyD88 pathways mediate immune responses against certain viruses such as West Nile virus and influenza virus. It has been shown that WW domain-containing protein (WWP) 2 and TRIM38 promote K48-linked ubiquitination of TRIF to induce its proteasome-dependent degradation, whereas TRIM32 induces the autophagic degradation of TRIF in a manner independent of ubiquitination (73-76). These E3s may function redundantly or cooperatively in a cell-type or signal specific manner. For example, WWP2 functions in bone marrow-derived macrophages (BMDMs) but not bone marrow-derived dendritic cells (BMDCs) and specifically regulates TLR3- but not TLR4-mediated innate immune and inflammatory responses, whereas TRIM38 and TRIM32 function in various types of cells and regulate both TLR3 and TLR4 signaling. The activation of MyD88 requires K63-linked ubiquitination at Lys231 after *Haemophilus influenzae* infection which is deconjugated by CYLD (77) and the E3s for this modification remain to be identified. The TLR-MyD88 signaling is turned down by TGF- β treatment which induces Smurf1/2-mediated K48-linked ubiquitination and degradation of MyD88 (78,79). In addition, Ndrp1 and Drosophila Pellino catalyze K48-linked ubiquitination and degradation of MyD88 (80,81). Although these E3s function as negative or positive regulators of TRIF or MyD88, their role in regulating cellular antiviral responses remains uninvestigated.

A number of E3s have been identified to catalyze K48-linked ubiquitination and proteasome-dependent degradation of VISA. Recently, tetherin has been found to recruit the E3 ubiquitin ligase membrane-associated RING-CH-8 (MARCH8) to catalyze K27-linked ubiquitin chains on MAVS at lysine 7 for autophagic degradation (82), and TRIM31 catalyzes K63-linked ubiquitination of VISA at Lys10, Lys311, and Lys461 to promote aggregation of VISA and the recruitment of TBK1 (24), thereby inhibiting or promoting cellular antiviral responses

and type I IFN induction. It has been so far unclear whether and how DUBs antagonize this process. About one dozen of E3s have been reported to catalyze K11-linked (RNF26), K27-linked (AMFR), K48-linked (RNF5, TRIM30 α , and TRIM29) or K63-linked (TRIM32, TRIM56, and MUL1) ubiquitination of MITA at various lysine residues (49,83-85). Recently, we demonstrated that USP18 recruits USP20 to deubiquitinate and stabilize MITA to promote type I IFN induction and USP13 directly removes K27-linked ubiquitin chains from MITA to turn down antiviral signaling (86,87). In addition, another study has shown that USP21 deconjugates K27- and K63-linked ubiquitin chains on MITA and restricts cellular antiviral signaling and autoimmunity (88). These studies indicate a highly dynamic regulation of MITA which facilitates efficient and appropriate immune responses against viruses.

In addition to autoubiquitination, TRAF3 and TRAF6 are also ubiquitinated by cIAP1/2, which is required for virus-triggered signaling (89). Interestingly, a recent study shows that estrogen receptor (ER) α inhibits vesicular stomatitis virus (VSV)-induced IRF3 activation via promoting K48-linked ubiquitination of TRAF3, and whether cIAP1/2 or other E3s are involved in this process is unknown (90). The K48-linked ubiquitination of TRAF3 can be reversed by OTU domain-containing ubiquitin aldehyde-binding protein 1 (OTUB1), in which NmrA like redox sensor 1 (NMRAL1 also known as HSCARG) is required (91). However, our previous study has demonstrated that OTUB1/2 remove K63-linked polyubiquitin chains from TRAF3 and TRAF6, thereby inhibiting virus-triggered induction of type I IFNs (92). We and others have shown that USP25 and MYSM1 deconjugate K48- and K63-linked ubiquitin chains from TRAF3 and promote or inhibit cellular antiviral signaling, respectively (93,94). It should be noted that TRAF3 also catalyzes K63-linked ubiquitination of ASC to promote inflammasome activation, indicating an essential crosstalk between virus-triggered type I IFN induction and IL-1 β production pathways (95).

Regulation of kinases and transcription factors

It has been previously shown that TBK1 undergoes deltax (DTX) 4-mediated K48-linked ubiquitination, and later we found that the kinase DYRK2-mediated phosphorylation on Ser527 of TBK1 is a prerequisite for its ubiquitination and degradation (95,96). The DLAI motif of VISA recruits MIB2 to promote K63-linked ubiquitination of TBK1 (97) and Song et al have characterized another E3 ligase RNF128 as an E3 mediating K63-linked ubiquitination of TBK1 at Lys30 and Lys401 to promote activation of TBK1 and type I IFN induction after viral infection (98). The activation and regulation of IKK ϵ by ubiquitination is less clear.

We and others have shown that forkhead box protein O1 (FOXO1) and multiple E3s such as RBCK1 and RAUL catalyze K48-linked ubiquitination and degradation of IRF3 (49). Recently, another E3 c-Cbl promotes K48-linked polyubiquitination and proteasomal degradation of IRF3 (99). In addition, linear ubiquitin chain assembly complex (LUBAC) catalyzes linear ubiquitination of IRF-3 at Lys193 and Lys313 to induce RLR-triggered apoptosis and blocks viral pathogenesis (100). IRF7 is ubiquitinated by TRAF6 and involved in TLR7/9-mediated type I IFN induction (33,101). The DUBs responsible for the reverse modifications of the kinases or transcription factors remain to be characterized.

SUMOYLATION AND DE-SUMOYLATION

SUMOylation has been shown to essentially engage PRRs-mediated signaling and type I IFN induction (102). It has previously been observed that RIG-I and MDA5 undergo SUMOylation

after viral infection, and MUL1 and PIAS2b are E3s for RIG-I and MDA5 SUMOylation, respectively (103-105). In a recent study, Hu et al. (106) have elegantly shown that TRIM38 mediates SUMOylation of RIG-I and MDA5 at Lys96/888 or Lys43/865, respectively. This SUMOylation prevents the K48-linked ubiquitination and degradation. At late time points after viral infection, the SUMOylation of RIG-I and MDA5 is removed by SENP2, which allows for K48-linked ubiquitination and degradation (106). Moreover, they further demonstrate that cGAS and MITA are also Sumoylated by TRIM38 and de-Sumoylated by SENP2 in a similar way (107). Results from another study shows that cGAS is Sumoylated at Lys335/372/382, and SENP7 removes Sumo molecules from cGAS, rendering the ability to sense DNA by cGAS (108). These studies together reveal dynamic SUMOylation and de-SUMOylation and the crosstalk with ubiquitination in modulating innate antiviral signaling.

The kinase TBK1 is also sumoylated at Lys694 which confers it antiviral activity, although the E3s for this process are unknown (109). Viral infection induces SUMOylation of IRF3 and IRF7 at Lys152 and Lys406, respectively, which negatively regulates their transcription activity (110). The E3s TRIM28 and PIAS1 mediate SUMOylation of IRF7 and IRF3 to repress their transcription activity (111,112). However, in another study, viral infection induces SUMOylation of IRF3 at Lys70 and Lys87 to stabilize IRF3, which are K48-linked ubiquitination sites. SENP2 de-Sumoylates IRF3 and renders IRF3 sensitive to ubiquitination and proteasome degradation (22). These data together suggest SUMOylation on different lysine residues of IRF3 or IRF7 may facilitate positive and negative roles of innate antiviral signaling. A systemic analysis of SUMOylation of host proteins has been conducted recently and it is hoped that more sumoylated proteins and their roles in viral infection will be uncovered in a near future (113,114).

ISGYLATION AND DE-ISGYLATION

ISG15 is an IFN-stimulated gene that can be conjugated to lysine residues of target proteins. The process is called ISGylation and required to mount efficient immune response against viruses. Firstly, it has been shown that genetically deletion of ISG15 in mice leads to hypersensitivity to viral infections (115). Secondly, deletion of USP18 or knock-in USP18^{C61A} increases ISGylation in cells and renders cells more resistant to viral infection after type I IFN treatment (116,117). Third, the USP18^{C61A} mice are resistant to viral infections (117). Later it has been shown that RIG-I and IRF3 are modified by ISG15, which impairs the K48-linked ubiquitination and degradation of RIG-I and IRF3 by RNF125 and Pin1 respectively and promotes type I IFN induction (118-120). Indeed, ISG15 is likely to target newly synthesized proteins including IFN-stimulated genes and viral proteins (120), which modulates the functions of host proteins and dominantly inhibits the functions of viral proteins. However, there is evidence suggesting that the free ISG15 also plays a role in antiviral responses, supported by the observation that deletion of E1 for ISGylation UBE1L protects mice from Chikungunya virus (CHIKV) infection (121). Together, the ISGylation and free ISG15 are essential for host defense against viral infections in mice.

The functions of ISG15 or ISGylation in humans may be different from those in mice. Human patients with ISG15 deficiency exhibit mycobacterial but not viral diseases, and human ISG15 deficient cells are not susceptible to viral infections. In contrast, the deficiency of ISG15 in human leads to reduced production of IFN- γ , indicating that human ISGylation is largely redundant for antiviral immunity and that ISG15 plays an essential role in IFN- γ production for

optimal antimycobacterial immunity (122). In another study, it is shown that ISG15-deficient patients display unanticipated cellular, immunological and clinical signs of autoinflammatory interferonopathies Aicardi-Goutières syndrome and spondyloenchondrodysplasia, which is due to the reduced expression of USP18, a negative regulator of type I IFN signaling (123). More recently, it has been demonstrated that USP18 deficiency in human increases ISGylation and hyper-activation of type I IFN signaling and results in the severe pseudo-toxoplasmosis, rubella, cytomegalovirus, and herpes simplex virus (TORCH) syndrome (124). These data collectively suggest that in humans ISGylation or ISG15 is essential to promote IFN- γ induction and restrict type I IFN signaling, thereby facilitating antibacterial immunity and avoiding interferonopathy. The targets of ISG15 modification and the mechanisms by which ISGylation exerts its function requires further investigations.

NEDDYLATION AND DE-NEDDYLATION

NEDD8 is a ubiquitin-like protein that activates the cullin-RING E3 ligases (CRLs) by conjugating to the conserved lysine residues on the C terminus of cullin proteins. The CRLs are widely involved in the regulation of ubiquitination in various processes including cellular antiviral responses. The most studied example is the F-box containing protein β -transducing repeat-containing protein (β TrCP), a subunit of the SKP1-cullin-F-box (SCF) complex which induces ubiquitination and degradation of phosphorylated I κ B α , a prerequisite for NF- κ B activation in response to various stimulations such as viral infection. Another CRL consisting of SOCS1 (suppressor of cytokine signaling)-cullin5-Rbx2 mediates ubiquitination and degradation of p65 (125). Although few CRLs have been identified to regulate antiviral signaling pathways, it is expected that dysfunction of NEDDylation regulates antiviral signaling by modulating ubiquitination of key proteins involved in the pathways. Indeed, recent studies have shown that inhibition of NEDDylation by the inhibitor MLN4924 disrupts viral latency and elicits cellular cytotoxicity in a dose-dependent manner (126) and that viruses can hijack the NEDDylation on CRLs to benefit replication (127,128). NEDDylation can occur on non-CRL proteins (18,129), but the E3s for this process remains largely unidentified. For example, TRIM40 promotes neddylation of IKK γ , which inhibits NF- κ B activation (130) and MyD88 is neddylated which inhibits dimerization of MyD88 and NF- κ B activity by antagonizing its ubiquitination (131).

The NEDDylation can be removed by CSN5 and NEDP1, which deconjugate NEDD8 from CRLs and non-CRL substrates or aberrant neddylated CRLs, respectively (132-134). It is so far unclear whether and how NEDP1-mediated de-NEDDylation of non-CRL substrates regulate virus-triggered PRRs-mediated signaling. A recent study has systemically analyzed neddylated proteins in the absence of NEDP1, which may provide information for future investigations (129).

CONCLUDING REMARKS

Although ubiquitination and deubiquitination have been extensively investigated in the regulation of cellular antiviral signaling, the exact dynamic regulation in specific cells in response to infection of distinct viruses still remains largely unknown and the roles of ubiquitin-like modifications in cellular antiviral signaling have just been emerging. The machinery involved in ubiquitin and ubiquitin-like modifications, the targets of such

modifications, and the crosstalk among these modifications are of great interest and have attracted increasing attentions from researchers worldwide. In addition, the complicated machinery could be targeted or even hijacked by viruses to facilitate viral replication (49,135). Accumulating evidence has suggested that viral structural or nonstructural proteins could directly modulate ubiquitin or ubiquitin-like modifications on key components involved in antiviral signaling or indirectly utilize host machinery to interfere with the cellular antiviral signaling. It is expected that huge progresses will be made to understand the machinery and strategies targeting the machinery will be developed to treat viral infection-related diseases in the next decade.

ACKNOWLEDGEMENTS

Studies in our lab are supported by grants from the Ministry of Science and Technology of the People's Republic of China (2014CB542601), National Natural Science Foundation of China (31521091, 31671454, and 31622036), Wuhan University (2042017kf0199 and 2042017kf0242), and State Key Laboratory of Veterinary Etiological Biology (SKLVEB2017KFKT004).

REFERENCES

1. Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. *Cold Spring Harb Symp Quant Biol* 1989;54:1-13.
[PUBMED](#) | [CROSSREF](#)
2. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. *Cell* 2010;140:805-820.
[PUBMED](#) | [CROSSREF](#)
3. Wu J, Chen ZJ. Innate immune sensing and signaling of cytosolic nucleic acids. *Annu Rev Immunol* 2014;32:461-488.
[PUBMED](#) | [CROSSREF](#)
4. Kawai T, Takahashi K, Sato S, Coban C, Kumar H, Kato H, Ishii KJ, Takeuchi O, Akira S. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. *Nat Immunol* 2005;6:981-988.
[PUBMED](#) | [CROSSREF](#)
5. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, Tschopp J. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. *Nature* 2005;437:1167-1172.
[PUBMED](#) | [CROSSREF](#)
6. Xu LG, Wang YY, Han KJ, Li LY, Zhai Z, Shu HB. VISA is an adapter protein required for virus-triggered IFN-beta signaling. *Mol Cell* 2005;19:727-740.
[PUBMED](#) | [CROSSREF](#)
7. Seth RB, Sun L, Ea CK, Chen ZJ. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. *Cell* 2005;122:669-682.
[PUBMED](#) | [CROSSREF](#)
8. Sun L, Wu J, Du F, Chen X, Chen ZJ. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. *Science* 2013;339:786-791.
[PUBMED](#) | [CROSSREF](#)
9. Li XD, Wu J, Gao D, Wang H, Sun L, Chen ZJ. Pivotal roles of cGAS-cGAMP signaling in antiviral defense and immune adjuvant effects. *Science* 2013;341:1390-1394.
[PUBMED](#) | [CROSSREF](#)
10. Chiu YH, Macmillan JB, Chen ZJ. RNA polymerase III detects cytosolic DNA and induces type I interferons through the RIG-I pathway. *Cell* 2009;138:576-591.
[PUBMED](#) | [CROSSREF](#)
11. Ablasser A, Bauernfeind F, Hartmann G, Latz E, Fitzgerald KA, Hornung V. RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. *Nat Immunol* 2009;10:1065-1072.
[PUBMED](#) | [CROSSREF](#)

12. Zhong B, Yang Y, Li S, Wang YY, Li Y, Diao F, Lei C, He X, Zhang L, Tien P, et al. The adaptor protein MITA links virus-sensing receptors to IRF3 transcription factor activation. *Immunity* 2008;29:538-550.
[PUBMED](#) | [CROSSREF](#)
13. Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. *Nature* 2008;455:674-678.
[PUBMED](#) | [CROSSREF](#)
14. Man SM, Karki R, Kanneganti TD. Molecular mechanisms and functions of pyroptosis, inflammatory caspases and inflammasomes in infectious diseases. *Immunol Rev* 2017;277:61-75.
[PUBMED](#) | [CROSSREF](#)
15. Yang J, Liu Z, Xiao TS. Post-translational regulation of inflammasomes. *Cell Mol Immunol* 2017;14:65-79.
[PUBMED](#) | [CROSSREF](#)
16. Komander D, Rape M. The ubiquitin code. *Annu Rev Biochem* 2012;81:203-229.
[PUBMED](#) | [CROSSREF](#)
17. Mevissen TE, Komander D. Mechanisms of deubiquitinase specificity and regulation. *Annu Rev Biochem* 2017;86:159-192.
[PUBMED](#) | [CROSSREF](#)
18. Enchev RI, Schulman BA, Peter M. Protein neddylation: beyond cullin-RING ligases. *Nat Rev Mol Cell Biol* 2015;16:30-44.
[PUBMED](#) | [CROSSREF](#)
19. dos Santos PF, Mansur DS. Beyond ISGylation: functions of free intracellular and extracellular ISG15. *J Interferon Cytokine Res* 2017;37:246-253.
[PUBMED](#) | [CROSSREF](#)
20. Dhingra N, Zhao X. A guide for targeted SUMO removal. *Genes Dev* 2017;31:719-720.
[PUBMED](#) | [CROSSREF](#)
21. Xia P, Wang S, Xiong Z, Ye B, Huang LY, Han ZG, Fan Z. IRTKS negatively regulates antiviral immunity through PCBP2 sumoylation-mediated MAVS degradation. *Nat Commun* 2015;6:8132.
[PUBMED](#) | [CROSSREF](#)
22. Yang P, Ma J, Zhang B, Duan H, He Z, Zeng J, Zeng X, Li D, Wang Q, Xiao Y, et al. CpG site-specific hypermethylation of p16INK4a in peripheral blood lymphocytes of PAH-exposed workers. *Cancer Epidemiol Biomarkers Prev* 2012;21:182-190.
[PUBMED](#) | [CROSSREF](#)
23. Skaug B, Chen ZJ. Emerging role of ISG15 in antiviral immunity. *Cell* 2010;143:187-190.
[PUBMED](#) | [CROSSREF](#)
24. Liu B, Zhang M, Chu H, Zhang H, Wu H, Song G, Wang P, Zhao K, Hou J, Wang X, et al. The ubiquitin E3 ligase TRIM31 promotes aggregation and activation of the signaling adaptor MAVS through Lys63-linked polyubiquitination. *Nat Immunol* 2017;18:214-224.
[PUBMED](#) | [CROSSREF](#)
25. Wang Q, Liu X, Cui Y, Tang Y, Chen W, Li S, Yu H, Pan Y, Wang C. The E3 ubiquitin ligase AMFR and INSIG1 bridge the activation of TBK1 kinase by modifying the adaptor STING. *Immunity* 2014;41:919-933.
[PUBMED](#) | [CROSSREF](#)
26. Zhang J, Hu MM, Wang YY, Shu HB. TRIM32 protein modulates type I interferon induction and cellular antiviral response by targeting MITA/STING protein for K63-linked ubiquitination. *J Biol Chem* 2012;287:28646-28655.
[PUBMED](#) | [CROSSREF](#)
27. Tsuchida T, Zou J, Saitoh T, Kumar H, Abe T, Matsuura Y, Kawai T, Akira S. The ubiquitin ligase TRIM56 regulates innate immune responses to intracellular double-stranded DNA. *Immunity* 2010;33:765-776.
[PUBMED](#) | [CROSSREF](#)
28. Michallet MC, Meylan E, Ermolaeva MA, Vazquez J, Rebsamen M, Curran J, Poeck H, Bscheider M, Hartmann G, König M, et al. TRADD protein is an essential component of the RIG-like helicase antiviral pathway. *Immunity* 2008;28:651-661.
[PUBMED](#) | [CROSSREF](#)
29. Liu S, Chen J, Cai X, Wu J, Chen X, Wu YT, Sun L, Chen ZJ. MAVS recruits multiple ubiquitin E3 ligases to activate antiviral signaling cascades. *ELife* 2013;2:e00785.
[PUBMED](#) | [CROSSREF](#)
30. Liu S, Cai X, Wu J, Cong Q, Chen X, Li T, Du F, Ren J, Wu YT, Grishin NV, et al. Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation. *Science* 2015;347:aaa2630.
[PUBMED](#) | [CROSSREF](#)
31. Shinohara ML, Lu L, Bu J, Werneck MB, Kobayashi KS, Glimcher LH, Cantor H. Osteopontin expression is essential for interferon-alpha production by plasmacytoid dendritic cells. *Nat Immunol* 2006;7:498-506.
[PUBMED](#) | [CROSSREF](#)

32. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, Shimada N, Ohba Y, Takaoka A, Yoshida N, et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. *Nature* 2005;434:772-777.
[PUBMED](#) | [CROSSREF](#)
33. Honda K, Ohba Y, Yanai H, Negishi H, Mizutani T, Takaoka A, Taya C, Taniguchi T. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. *Nature* 2005;434:1035-1040.
[PUBMED](#) | [CROSSREF](#)
34. Lu B, Ren Y, Sun X, Han C, Wang H, Chen Y, Peng Q, Cheng Y, Cheng X, Zhu Q, et al. Induction of INK1T by viral infection negatively regulates antiviral responses through inhibiting phosphorylation of p65 and IRF3. *Cell Host Microbe* 2017;22:86-98.e4.
[PUBMED](#) | [CROSSREF](#)
35. Jin J, Hu H, Li HS, Yu J, Xiao Y, Brittain GC, Zou Q, Cheng X, Mallette FA, Watowich SS, et al. Noncanonical NF- κ B pathway controls the production of type I interferons in antiviral innate immunity. *Immunity* 2014;40:342-354.
[PUBMED](#) | [CROSSREF](#)
36. Mathur A, Hayward JA, Man SM. Molecular mechanisms of inflammasome signaling. *J Leukoc Biol*. doi: 10.1189/jlb.3MR0617-250R.
[PUBMED](#) | [CROSSREF](#)
37. Schroder K, Tschopp J. The inflammasomes. *Cell* 2010;140:821-832.
[PUBMED](#) | [CROSSREF](#)
38. Rathinam VA, Jiang Z, Waggoner SN, Sharma S, Cole LE, Waggoner L, Vanaja SK, Monks BG, Ganesan S, Latz E, et al. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. *Nat Immunol* 2010;11:395-402.
[PUBMED](#) | [CROSSREF](#)
39. Singh VV, Kerur N, Bottero V, Dutta S, Chakraborty S, Ansari MA, Paudel N, Chikoti L, Chandran B. Kaposi's sarcoma-associated herpesvirus latency in endothelial and B cells activates gamma interferon-inducible protein 16-mediated inflammasomes. *J Virol* 2013;87:4417-4431.
[PUBMED](#) | [CROSSREF](#)
40. Johnson KE, Chikoti L, Chandran B. Herpes simplex virus 1 infection induces activation and subsequent inhibition of the IFI16 and NLRP3 inflammasomes. *J Virol* 2013;87:5005-5018.
[PUBMED](#) | [CROSSREF](#)
41. Poeck H, Bscheidt M, Gross O, Finger K, Roth S, Rebsamen M, Hanneschläger N, Schlee M, Rothenfusser S, Barchet W, et al. Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1 beta production. *Nat Immunol* 2010;11:63-69.
[PUBMED](#) | [CROSSREF](#)
42. Chattergoon MA, Latanich R, Quinn J, Winter ME, Buckheit RW 3rd, Blankson JN, Pardoll D, Cox AL. HIV and HCV activate the inflammasome in monocytes and macrophages via endosomal Toll-like receptors without induction of type 1 interferon. *PLoS Pathog* 2014;10:e1004082.
[PUBMED](#) | [CROSSREF](#)
43. Ogura Y, Sutterwala FS, Flavell RA. The inflammasome: first line of the immune response to cell stress. *Cell* 2006;126:659-662.
[PUBMED](#) | [CROSSREF](#)
44. Oda T, Akaike T, Hamamoto T, Suzuki F, Hirano T, Maeda H. Oxygen radicals in influenza-induced pathogenesis and treatment with pyran polymer-conjugated SOD. *Science* 1989;244:974-976.
[PUBMED](#) | [CROSSREF](#)
45. Ichinohe T, Pang IK, Iwasaki A. Influenza virus activates inflammasomes via its intracellular M2 ion channel. *Nat Immunol* 2010;11:404-410.
[PUBMED](#) | [CROSSREF](#)
46. Rahman MM, McFadden G. Myxoma virus lacking the pyrin-like protein M013 is sensed in human myeloid cells by both NLRP3 and multiple Toll-like receptors, which independently activate the inflammasome and NF- κ B innate response pathways. *J Virol* 2011;85:12505-12517.
[PUBMED](#) | [CROSSREF](#)
47. Martin BN, Wang C, Willette-Brown J, Herjan T, Gulen MF, Zhou H, Bulek K, Franchi L, Sato T, Alnemri ES, et al. IKK α negatively regulates ASC-dependent inflammasome activation. *Nat Commun* 2014;5:4977.
[PUBMED](#) | [CROSSREF](#)
48. Wang Y, Ning X, Gao P, Wu S, Sha M, Lv M, Zhou X, Gao J, Fang R, Meng G, et al. Inflammasome activation triggers caspase-1-mediated cleavage of cGAS to regulate responses to DNA virus infection. *Immunity* 2017;46:393-404.
[PUBMED](#) | [CROSSREF](#)

49. Lin D, Zhong B. Regulation of cellular innate antiviral signaling by ubiquitin modification. *Acta Biochim Biophys Sin (Shanghai)* 2015;47:149-155.
[PUBMED](#) | [CROSSREF](#)
50. Liu W, Li J, Zheng W, Shang Y, Zhao Z, Wang S, Bi Y, Zhang S, Xu C, Duan Z, et al. Cyclophilin A-regulated ubiquitination is critical for RIG-I-mediated antiviral immune responses. *ELife* 2017;6:e24425.
[PUBMED](#) | [CROSSREF](#)
51. Gack MU, Shin YC, Joo CH, Urano T, Liang C, Sun L, Takeuchi O, Akira S, Chen Z, Inoue S, et al. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. *Nature* 2007;446:916-920.
[PUBMED](#) | [CROSSREF](#)
52. Shi Y, Yuan B, Zhu W, Zhang R, Li L, Hao X, Chen S, Hou F. Ube2D3 and Ube2N are essential for RIG-I-mediated MAVS aggregation in antiviral innate immunity. *Nat Commun* 2017;8:15138.
[PUBMED](#) | [CROSSREF](#)
53. Sun X, Xian H, Tian S, Sun T, Qin Y, Zhang S, Cui J. A hierarchical mechanism of RIG-I ubiquitination provides sensitivity, robustness and synergy in antiviral immune responses. *Sci Rep* 2016;6:29263.
[PUBMED](#) | [CROSSREF](#)
54. Xian H, Xie W, Yang S, Liu Q, Xia X, Jin S, Sun T, Cui J. Stratified ubiquitination of RIG-I creates robust immune response and induces selective gene expression. *Sci Adv* 2017;3:e1701764.
[PUBMED](#) | [CROSSREF](#)
55. Hao Q, Jiao S, Shi Z, Li C, Meng X, Zhang Z, Wang Y, Song X, Wang W, Zhang R, et al. A non-canonical role of the p97 complex in RIG-I antiviral signaling. *EMBO J* 2015;34:2903-2920.
[PUBMED](#) | [CROSSREF](#)
56. Wang W, Jiang M, Liu S, Zhang S, Liu W, Ma Y, Zhang L, Zhang J, Cao X. RNF122 suppresses antiviral type I interferon production by targeting RIG-I CARDS to mediate RIG-I degradation. *Proc Natl Acad Sci U S A* 2016;113:9581-9586.
[PUBMED](#) | [CROSSREF](#)
57. Arimoto K, Takahashi H, Hishiki T, Konishi H, Fujita T, Shimotohno K. Negative regulation of the RIG-I signaling by the ubiquitin ligase RNF125. *Proc Natl Acad Sci U S A* 2007;104:7500-7505.
[PUBMED](#) | [CROSSREF](#)
58. Chen W, Han C, Xie B, Hu X, Yu Q, Shi L, Wang Q, Li D, Wang J, Zheng P, et al. Induction of Siglec-G by RNA viruses inhibits the innate immune response by promoting RIG-I degradation. *Cell* 2013;152:467-478.
[PUBMED](#) | [CROSSREF](#)
59. Zhao C, Jia M, Song H, Yu Z, Wang W, Li Q, Zhang L, Zhao W, Cao X. The E3 ubiquitin ligase TRIM40 attenuates antiviral immune responses by targeting MDA5 and RIG-I. *Cell Rep* 2017;21:1613-1623.
[PUBMED](#) | [CROSSREF](#)
60. Zhang H, Wang D, Zhong H, Luo R, Shang M, Liu D, Chen H, Fang L, Xiao S. Ubiquitin-specific protease 15 negatively regulates virus-induced type I interferon signaling via catalytically-dependent and -independent mechanisms. *Sci Rep* 2015;5:11220.
[PUBMED](#) | [CROSSREF](#)
61. Pauli EK, Chan YK, Davis ME, Gableske S, Wang MK, Feister KF, Gack MU. The ubiquitin-specific protease USP15 promotes RIG-I-mediated antiviral signaling by deubiquitylating TRIM25. *Sci Signal* 2014;7:ra3.
[PUBMED](#) | [CROSSREF](#)
62. Zhang M, Wu X, Lee AJ, Jin W, Chang M, Wright A, Imaizumi T, Sun SC. Regulation of IkappaB kinase-related kinases and antiviral responses by tumor suppressor CYLD. *J Biol Chem* 2008;283:18621-18626.
[PUBMED](#) | [CROSSREF](#)
63. Chen R, Zhang L, Zhong B, Tan B, Liu Y, Shu HB. The ubiquitin-specific protease 17 is involved in virus-triggered type I IFN signaling. *Cell Res* 2010;20:802-811.
[PUBMED](#) | [CROSSREF](#)
64. Wang L, Zhao W, Zhang M, Wang P, Zhao K, Zhao X, Yang S, Gao C. USP4 positively regulates RIG-I-mediated antiviral response through deubiquitination and stabilization of RIG-I. *J Virol* 2013;87:4507-4515.
[PUBMED](#) | [CROSSREF](#)
65. Cui J, Song Y, Li Y, Zhu Q, Tan P, Qin Y, Wang HY, Wang RF. USP3 inhibits type I interferon signaling by deubiquitinating RIG-I-like receptors. *Cell Res* 2014;24:400-416.
[PUBMED](#) | [CROSSREF](#)
66. Fan Y, Mao R, Yu Y, Liu S, Shi Z, Cheng J, Zhang H, An L, Zhao Y, Xu X, et al. USP21 negatively regulates antiviral response by acting as a RIG-I deubiquitinase. *J Exp Med* 2014;211:313-328.
[PUBMED](#) | [CROSSREF](#)
67. Lang X, Tang T, Jin T, Ding C, Zhou R, Jiang W. TRIM65-catalyzed ubiquitination is essential for MDA5-mediated antiviral innate immunity. *J Exp Med* 2017;214:459-473.
[PUBMED](#) | [CROSSREF](#)

68. Wang Q, Huang L, Hong Z, Lv Z, Mao Z, Tang Y, Kong X, Li S, Cui Y, Liu H, et al. The E3 ubiquitin ligase RNF185 facilitates the cGAS-mediated innate immune response. *PLoS Pathog* 2017;13:e1006264.
[PUBMED](#) | [CROSSREF](#)
69. Chen M, Meng Q, Qin Y, Liang P, Tan P, He L, Zhou Y, Chen Y, Huang J, Wang RF, et al. TRIM14 inhibits cGAS degradation mediated by selective autophagy receptor p62 to promote innate immune responses. *Mol Cell* 2016;64:105-119.
[PUBMED](#) | [CROSSREF](#)
70. Shi CS, Shenderov K, Huang NN, Kabat J, Abu-Asab M, Fitzgerald KA, Sher A, Kehrl JH. Activation of autophagy by inflammatory signals limits IL-1 β production by targeting ubiquitinated inflammasomes for destruction. *Nat Immunol* 2012;13:255-263.
[PUBMED](#) | [CROSSREF](#)
71. Han S, Lear TB, Jerome JA, Rajbhandari S, Snavelly CA, Gulick DL, Gibson KF, Zou C, Chen BB, Mallampalli RK. Lipopolysaccharide primes the NALP3 inflammasome by inhibiting its ubiquitination and degradation mediated by the SCFFBXL2 E3 ligase. *J Biol Chem* 2015;290:18124-18133.
[PUBMED](#) | [CROSSREF](#)
72. Yan Y, Jiang W, Liu L, Wang X, Ding C, Tian Z, Zhou R. Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome. *Cell* 2015;160:62-73.
[PUBMED](#) | [CROSSREF](#)
73. Xue Q, Zhou Z, Lei X, Liu X, He B, Wang J, Hung T. TRIM38 negatively regulates TLR3-mediated IFN- β signaling by targeting TRIF for degradation. *PLoS One* 2012;7:e46825.
[PUBMED](#) | [CROSSREF](#)
74. Hu MM, Xie XQ, Yang Q, Liao CY, Ye W, Lin H, Shu HB. TRIM38 negatively regulates TLR3/4-mediated innate immune and inflammatory responses by two sequential and distinct mechanisms. *J Immunol* 2015;195:4415-4425.
[PUBMED](#) | [CROSSREF](#)
75. Yang Y, Liao B, Wang S, Yan B, Jin Y, Shu HB, Wang YY. E3 ligase WWP2 negatively regulates TLR3-mediated innate immune response by targeting TRIF for ubiquitination and degradation. *Proc Natl Acad Sci U S A* 2013;110:5115-5120.
[PUBMED](#) | [CROSSREF](#)
76. Yang Q, Liu TT, Lin H, Zhang M, Wei J, Luo WW, Hu YH, Zhong B, Hu MM, Shu HB. TRIM32-TAX1BP1-dependent selective autophagic degradation of TRIF negatively regulates TLR3/4-mediated innate immune responses. *PLoS Pathog* 2017;13:e1006600.
[PUBMED](#) | [CROSSREF](#)
77. Lee BC, Miyata M, Lim JH, Li JD. Deubiquitinase CYLD acts as a negative regulator for bacterium NTHi-induced inflammation by suppressing K63-linked ubiquitination of MyD88. *Proc Natl Acad Sci U S A* 2016;113:E165-E171.
[PUBMED](#) | [CROSSREF](#)
78. Naiki Y, Michelsen KS, Zhang W, Chen S, Doherty TM, Arditi M. Transforming growth factor-beta differentially inhibits MyD88-dependent, but not TRAM- and TRIF-dependent, lipopolysaccharide-induced TLR4 signaling. *J Biol Chem* 2005;280:5491-5495.
[PUBMED](#) | [CROSSREF](#)
79. Strickson S, Campbell DG, Emmerich CH, Knebel A, Plater L, Ritorto MS, Shpiro N, Cohen P. The anti-inflammatory drug BAY 11-7082 suppresses the MyD88-dependent signalling network by targeting the ubiquitin system. *Biochem J* 2013;451:427-437.
[PUBMED](#) | [CROSSREF](#)
80. Ji S, Sun M, Zheng X, Li L, Sun L, Chen D, Sun Q. Cell-surface localization of Pellino antagonizes Toll-mediated innate immune signalling by controlling MyD88 turnover in Drosophila. *Nat Commun* 2014;5:3458.
[PUBMED](#) | [CROSSREF](#)
81. Wang C, Chen T, Zhang J, Yang M, Li N, Xu X, Cao X. The E3 ubiquitin ligase Nrdp1 'preferentially' promotes TLR-mediated production of type I interferon. *Nat Immunol* 2009;10:744-752.
[PUBMED](#) | [CROSSREF](#)
82. Jin S, Tian S, Luo M, Xie W, Liu T, Duan T, Wu Y, Cui J. Tetherin suppresses type I interferon signaling by targeting MAVS for NDP52-mediated selective autophagic degradation in human cells. *Mol Cell* 2017;68:308-322.e4.
[PUBMED](#) | [CROSSREF](#)
83. Xing J, Zhang A, Zhang H, Wang J, Li XC, Zeng MS, Zhang Z. TRIM29 promotes DNA virus infections by inhibiting innate immune response. *Nat Commun* 2017;8:945.
[PUBMED](#) | [CROSSREF](#)

84. Ni G, Konno H, Barber GN. Ubiquitination of STING at lysine 224 controls IRF3 activation. *Sci Immunol* 2017;2:eaah7119.
[PUBMED](#) | [CROSSREF](#)
85. Wang Y, Lian Q, Yang B, Yan S, Zhou H, He L, Lin G, Lian Z, Jiang Z, Sun B. TRIM30a is a negative-feedback regulator of the intracellular DNA and DNA virus-triggered response by targeting STING. *PLoS Pathog* 2015;11:e1005012.
[PUBMED](#) | [CROSSREF](#)
86. Zhang M, Zhang MX, Zhang Q, Zhu GF, Yuan L, Zhang DE, Zhu Q, Yao J, Shu HB, Zhong B. USP18 recruits USP20 to promote innate antiviral response through deubiquitinating STING/MITA. *Cell Res* 2016;26:1302-1319.
[PUBMED](#) | [CROSSREF](#)
87. Sun H, Zhang Q, Jing YY, Zhang M, Wang HY, Cai Z, Liuyu T, Zhang ZD, Xiong TC, Wu Y, et al. USP13 negatively regulates antiviral responses by deubiquitinating STING. *Nat Commun* 2017;8:15534.
[PUBMED](#) | [CROSSREF](#)
88. Chen Y, Wang L, Jin J, Luan Y, Chen C, Li Y, Chu H, Wang X, Liao G, Yu Y, et al. p38 inhibition provides anti-DNA virus immunity by regulation of USP21 phosphorylation and STING activation. *J Exp Med* 2017;214:991-1010.
[PUBMED](#) | [CROSSREF](#)
89. Mao AP, Li S, Zhong B, Li Y, Yan J, Li Q, Teng C, Shu HB. Virus-triggered ubiquitination of TRAF3/6 by cIAP1/2 is essential for induction of interferon-beta (IFN-beta) and cellular antiviral response. *J Biol Chem* 2010;285:9470-9476.
[PUBMED](#) | [CROSSREF](#)
90. Wang C, Huang Y, Sheng J, Huang H, Zhou J. Estrogen receptor alpha inhibits RLR-mediated immune response via ubiquitinating TRAF3. *Cell Signal* 2015;27:1977-1983.
[PUBMED](#) | [CROSSREF](#)
91. Peng Y, Xu R, Zheng X. HSCARG negatively regulates the cellular antiviral RIG-I like receptor signaling pathway by inhibiting TRAF3 ubiquitination via recruiting OTUB1. *PLoS Pathog* 2014;10:e1004041.
[PUBMED](#) | [CROSSREF](#)
92. Li S, Zheng H, Mao AP, Zhong B, Li Y, Liu Y, Gao Y, Ran Y, Tien P, Shu HB. Regulation of virus-triggered signaling by OTUB1- and OTUB2-mediated deubiquitination of TRAF3 and TRAF6. *J Biol Chem* 2010;285:4291-4297.
[PUBMED](#) | [CROSSREF](#)
93. Lin D, Zhang M, Zhang MX, Ren Y, Jin J, Zhao Q, Pan Z, Wu M, Shu HB, Dong C, et al. Induction of USP25 by viral infection promotes innate antiviral responses by mediating the stabilization of TRAF3 and TRAF6. *Proc Natl Acad Sci U S A* 2015;112:11324-11329.
[PUBMED](#) | [CROSSREF](#)
94. Panda S, Nilsson JA, Gekara NO. Deubiquitinase MYSM1 regulates innate immunity through inactivation of TRAF3 and TRAF6 complexes. *Immunity* 2015;43:647-659.
[PUBMED](#) | [CROSSREF](#)
95. Guan K, Wei C, Zheng Z, Song T, Wu F, Zhang Y, Cao Y, Ma S, Chen W, Xu Q, et al. MAVS promotes inflammasome activation by targeting ASC for K63-linked ubiquitination via the E3 ligase TRAF3. *J Immunol* 2015;194:4880-4890.
[PUBMED](#) | [CROSSREF](#)
96. An T, Li S, Pan W, Tien P, Zhong B, Shu HB, Wu S. DYRK2 negatively regulates type I interferon induction by promoting TBK1 degradation via Ser527 phosphorylation. *PLoS Pathog* 2015;11:e1005179.
[PUBMED](#) | [CROSSREF](#)
97. Wildling L, Unterauer B, Zhu R, Rupprecht A, Haselgrübler T, Rankl C, Ebner A, Vater D, Pollheimer P, Pohl EE, et al. Linking of sensor molecules with amino groups to amino-functionalized AFM tips. *Bioconjug Chem* 2011;22:1239-1248.
[PUBMED](#) | [CROSSREF](#)
98. Song G, Liu B, Li Z, Wu H, Wang P, Zhao K, Jiang G, Zhang L, Gao C. E3 ubiquitin ligase RNF128 promotes innate antiviral immunity through K63-linked ubiquitination of TBK1. *Nat Immunol* 2016;17:1342-1351.
[PUBMED](#) | [CROSSREF](#)
99. Zhao X, Zhu H, Yu J, Li H, Ge J, Chen W. c-Cbl-mediated ubiquitination of IRF3 negatively regulates IFN- β production and cellular antiviral response. *Cell Signal* 2016;28:1683-1693.
[PUBMED](#) | [CROSSREF](#)
100. Chattopadhyay S, Kuzmanovic T, Zhang Y, Wetzel JL, Sen GC. Ubiquitination of the transcription factor IRF-3 activates RIPA, the apoptotic pathway that protects mice from viral pathogenesis. *Immunity* 2016;44:1151-1161.
[PUBMED](#) | [CROSSREF](#)

101. Ning S, Campos AD, Darnay BG, Bentz GL, Pagano JS. TRAF6 and the three C-terminal lysine sites on IRF7 are required for its ubiquitination-mediated activation by the tumor necrosis factor receptor family member latent membrane protein 1. *Mol Cell Biol* 2008;28:6536-6546.
[PUBMED](#) | [CROSSREF](#)
102. Decque A, Joffre O, Magalhaes JG, Cossec JC, Blecher-Gonen R, Lapaquette P, Silvin A, Manel N, Joubert PE, Seeler JS, et al. Sumoylation coordinates the repression of inflammatory and anti-viral gene-expression programs during innate sensing. *Nat Immunol* 2016;17:140-149.
[PUBMED](#) | [CROSSREF](#)
103. Mi Z, Fu J, Xiong Y, Tang H. SUMOylation of RIG-I positively regulates the type I interferon signaling. *Protein Cell* 2010;1:275-283.
[PUBMED](#) | [CROSSREF](#)
104. Fu J, Xiong Y, Xu Y, Cheng G, Tang H. MDA5 is SUMOylated by PIAS2 β in the upregulation of type I interferon signaling. *Mol Immunol* 2011;48:415-422.
[PUBMED](#) | [CROSSREF](#)
105. Doiron K, Goyon V, Coyaude E, Rajapakse S, Raught B, McBride HM. The dynamic interacting landscape of MAPL reveals essential functions for SUMOylation in innate immunity. *Sci Rep* 2017;7:107.
[PUBMED](#) | [CROSSREF](#)
106. Hu MM, Liao CY, Yang Q, Xie XQ, Shu HB. Innate immunity to RNA virus is regulated by temporal and reversible sumoylation of RIG-I and MDA5. *J Exp Med* 2017;214:973-989.
[PUBMED](#) | [CROSSREF](#)
107. Hu MM, Yang Q, Xie XQ, Liao CY, Lin H, Liu TT, Yin L, Shu HB. Sumoylation promotes the stability of the DNA sensor cGAS and the adaptor STING to regulate the kinetics of response to DNA virus. *Immunity* 2016;45:555-569.
[PUBMED](#) | [CROSSREF](#)
108. Cui Y, Yu H, Zheng X, Peng R, Wang Q, Zhou Y, Wang R, Wang J, Qu B, Shen N, et al. SENP7 potentiates cGAS activation by relieving SUMO-mediated inhibition of cytosolic DNA sensing. *PLoS Pathog* 2017;13:e1006156.
[PUBMED](#) | [CROSSREF](#)
109. Sankineni S, Cho Y, Hosseini N, Kolliputi N. Does pIgR down-regulation in COPD cause reprogramming of bronchial epithelium? *Lung* 2015;193:1-2.
[PUBMED](#) | [CROSSREF](#)
110. Kubota T, Matsuoka M, Chang TH, Tailor P, Sasaki T, Tashiro M, Kato A, Ozato K. Virus infection triggers SUMOylation of IRF3 and IRF7, leading to the negative regulation of type I interferon gene expression. *J Biol Chem* 2008;283:25660-25670.
[PUBMED](#) | [CROSSREF](#)
111. Liang Q, Deng H, Li X, Wu X, Tang Q, Chang TH, Peng H, Rauscher FJ 3rd, Ozato K, Zhu F. Tripartite motif-containing protein 28 is a small ubiquitin-related modifier E3 ligase and negative regulator of IFN regulatory factor 7. *J Immunol* 2011;187:4754-4763.
[PUBMED](#) | [CROSSREF](#)
112. Li R, Pan Y, Shi DD, Zhang Y, Zhang J. PIAS1 negatively modulates virus triggered type I IFN signaling by blocking the DNA binding activity of IRF3. *Antiviral Res* 2013;100:546-554.
[PUBMED](#) | [CROSSREF](#)
113. Lumpkin RJ, Gu H, Zhu Y, Leonard M, Ahmad AS, Clauser KR, Meyer JG, Bennett EJ, Komives EA. Site-specific identification and quantitation of endogenous SUMO modifications under native conditions. *Nat Commun* 2017;8:1171.
[PUBMED](#) | [CROSSREF](#)
114. Lamoliatte F, McManus FP, Maarifi G, Chelbi-Alix MK, Thibault P. Uncovering the SUMOylation and ubiquitylation crosstalk in human cells using sequential peptide immunopurification. *Nat Commun* 2017;8:14109.
[PUBMED](#) | [CROSSREF](#)
115. Lenschow DJ, Lai C, Frias-Staheli N, Giannakopoulos NV, Lutz A, Wolff T, Osiaik A, Levine B, Schmidt RE, Garcia-Sastre A, et al. IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. *Proc Natl Acad Sci U S A* 2007;104:1371-1376.
[PUBMED](#) | [CROSSREF](#)
116. Ritchie KJ, Hahn CS, Kim KI, Yan M, Rosario D, Li L, de la Torre JC, Zhang DE. Role of ISG15 protease UBP43 (USP18) in innate immunity to viral infection. *Nat Med* 2004;10:1374-1378.
[PUBMED](#) | [CROSSREF](#)
117. Ketscher L, Hannß R, Morales DJ, Basters A, Guerra S, Goldmann T, Hausmann A, Prinz M, Naumann R, Pekosz A, et al. Selective inactivation of USP18 isopeptidase activity *in vivo* enhances ISG15 conjugation and viral resistance. *Proc Natl Acad Sci U S A* 2015;112:1577-1582.
[PUBMED](#) | [CROSSREF](#)

118. Arimoto K, Konishi H, Shimotohno K. UbcH8 regulates ubiquitin and ISG15 conjugation to RIG-I. *Mol Immunol* 2008;45:1078-1084.
[PUBMED](#) | [CROSSREF](#)
119. Lu G, Reinert JT, Pitha-Rowe I, Okumura A, Kellum M, Knobloch KP, Hassel B, Pitha PM. ISG15 enhances the innate antiviral response by inhibition of IRF-3 degradation. *Cell Mol Biol (Noisy-le-grand)* 2006;52:29-41.
[PUBMED](#)
120. Shi HX, Yang K, Liu X, Liu XY, Wei B, Shan YF, Zhu LH, Wang C. Positive regulation of interferon regulatory factor 3 activation by Herc5 via ISG15 modification. *Mol Cell Biol* 2010;30:2424-2436.
[PUBMED](#) | [CROSSREF](#)
121. Werneke SW, Schilte C, Rohatgi A, Monte KJ, Michault A, Arenzana-Seisdedos F, Vanlandingham DL, Higgs S, Fontanet A, Albert ML, et al. ISG15 is critical in the control of Chikungunya virus infection independent of UBE1L mediated conjugation. *PLoS Pathog* 2011;7:e1002322.
[PUBMED](#) | [CROSSREF](#)
122. Bogunovic D, Byun M, Durfee LA, Abhyankar A, Sanal O, Mansouri D, Salem S, Radovanovic I, Grant AV, Adimi P, et al. Mycobacterial disease and impaired IFN- γ immunity in humans with inherited ISG15 deficiency. *Science* 2012;337:1684-1688.
[PUBMED](#) | [CROSSREF](#)
123. Zhang X, Bogunovic D, Payelle-Brogard B, Francois-Newton V, Speer SD, Yuan C, Volpi S, Li Z, Sanal O, Mansouri D, et al. Human intracellular ISG15 prevents interferon- α/β over-amplification and auto-inflammation. *Nature* 2015;517:89-93.
[PUBMED](#) | [CROSSREF](#)
124. Meuwissen ME, Schot R, Buta S, Oudesluijs G, Tinschert S, Speer SD, Li Z, van Unen L, Heijnsman D, Goldmann T, et al. Human USP18 deficiency underlies type 1 interferonopathy leading to severe pseudo-TORCH syndrome. *J Exp Med* 2016;213:1163-1174.
[PUBMED](#) | [CROSSREF](#)
125. Strebovsky J, Walker P, Lang R, Dalpke AH. Suppressor of cytokine signaling 1 (SOCS1) limits NF κ B signaling by decreasing p65 stability within the cell nucleus. *FASEB J* 2011;25:863-874.
[PUBMED](#) | [CROSSREF](#)
126. Chang PJ, Chen LW, Chen LY, Hung CH, Shih YJ, Wang SS. Effects of the NEDD8-activating enzyme inhibitor MLN4924 on lytic reactivation of Kaposi's sarcoma-associated herpesvirus. *J Virol* 2017;91:e00505-17.
[PUBMED](#) | [CROSSREF](#)
127. Davis KA, Morelli M, Patton JT. Rotavirus NSP1 requires casein kinase II-mediated phosphorylation for hijacking of cullin-RING ligases. *MBio* 2017;8:e01213-17.
[PUBMED](#) | [CROSSREF](#)
128. Ding S, Mooney N, Li B, Kelly MR, Feng N, Loktev AV, Sen A, Patton JT, Jackson PK, Greenberg HB. Comparative proteomics reveals strain-specific β -TrCP degradation via rotavirus NSP1 hijacking a host cullin-3-Rbx1 complex. *PLoS Pathog* 2016;12:e1005929.
[PUBMED](#) | [CROSSREF](#)
129. Coleman KE, Békés M, Chapman JR, Crist SB, Jones MJ, Ueberheide BM, Huang TT. SENP8 limits aberrant neddylation of NEDD8 pathway components to promote cullin-RING ubiquitin ligase function. *ELife* 2017;6:e24325.
[PUBMED](#) | [CROSSREF](#)
130. Noguchi K, Okumura F, Takahashi N, Kataoka A, Kamiyama T, Todo S, Hatakeyama S. TRIM40 promotes neddylation of IKK γ and is downregulated in gastrointestinal cancers. *Carcinogenesis* 2011;32:995-1004.
[PUBMED](#) | [CROSSREF](#)
131. Yan F, Guan J, Peng Y, Zheng X. MyD88 NEDDylation negatively regulates MyD88-dependent NF- κ B signaling through antagonizing its ubiquitination. *Biochem Biophys Res Commun* 2017;482:632-637.
[PUBMED](#) | [CROSSREF](#)
132. Chan Y, Yoon J, Wu JT, Kim HJ, Pan KT, Yim J, Chien CT. DEN1 deneddylates non-cullin proteins *in vivo*. *J Cell Sci* 2008;121:3218-3223.
[PUBMED](#) | [CROSSREF](#)
133. Mendoza HM, Shen LN, Botting C, Lewis A, Chen J, Ink B, Hay RT. NEDP1, a highly conserved cysteine protease that deNEDDylates Cullins. *J Biol Chem* 2003;278:25637-25643.
[PUBMED](#) | [CROSSREF](#)
134. Wu K, Yamoah K, Dolios G, Gan-Erdene T, Tan P, Chen A, Lee CG, Wei N, Wilkinson KD, Wang R, et al. DEN1 is a dual function protease capable of processing the C terminus of Nedd8 and deconjugating hyper-neddylated CUL1. *J Biol Chem* 2003;278:28882-28891.
[PUBMED](#) | [CROSSREF](#)

135. Kumari P, Kumar H. Viral deubiquitinases: role in evasion of anti-viral innate immunity. *Crit Rev Microbiol*. doi: 10.1080/1040841X.2017.1368999.
[PUBMED](#) | [CROSSREF](#)
136. Zhao K, Zhang Q, Li X, Zhao D, Liu Y, Shen Q, Yang M, Wang C, Li N, Cao X. Cytoplasmic STAT4 promotes antiviral type I IFN production by blocking CHIP-mediated degradation of RIG-I. *J Immunol* 2016;196:1209-1217.
[PUBMED](#) | [CROSSREF](#)
137. Ye JS, Kim N, Lee KJ, Nam YR, Lee U, Joo CH. Lysine 63-linked TANK-binding kinase 1 ubiquitination by mindbomb E3 ubiquitin protein ligase 2 is mediated by the mitochondrial antiviral signaling protein. *J Virol* 2014;88:12765-12776.
[PUBMED](#) | [CROSSREF](#)
138. Yu Z, Song H, Jia M, Zhang J, Wang W, Li Q, Zhang L, Zhao W. USP1-UAF1 deubiquitinase complex stabilizes TBK1 and enhances antiviral responses. *J Exp Med* 2017;214:3553-3563.
[PUBMED](#) | [CROSSREF](#)
139. Cui J, Li Y, Zhu L, Liu D, Songyang Z, Wang HY, Wang RF. NLRP4 negatively regulates type I interferon signaling by targeting the kinase TBK1 for degradation via the ubiquitin ligase DTX4. *Nat Immunol* 2012;13:387-395.
[PUBMED](#) | [CROSSREF](#)
140. Saul VV, Niedenthal R, Pich A, Weber F, Schmitz ML. SUMO modification of TBK1 at the adaptor-binding C-terminal coiled-coil domain contributes to its antiviral activity. *Biochim Biophys Acta* 2015;1853:136-143.
[PUBMED](#) | [CROSSREF](#)
141. Duong BH, Onizawa M, Osés-Prieto JA, Advincula R, Burlingame A, Malynn BA, Ma A. A20 restricts ubiquitination of pro-interleukin-1 β protein complexes and suppresses NLRP3 inflammasome activity. *Immunity* 2015;42:55-67.
[PUBMED](#) | [CROSSREF](#)